NLRP3-Mediated Inflammation: Novel Strategy for Neurodegenerative & Cardiometabolic Disease Intervention
Time: 11:30 am
day: Conference Day One AM
Details:
- Characterizing NLRP3-driven inflammatory pathways across neurodegenerative and cardiometabolic diseases
- Advancing development of VTX3232 as a CNS-penetrant oral NLRP3 inhibitor to address high unmet clinical needs
- Demonstrating IL-1B and IL-6 modulation as a mechanism to impact both central and peripheral inflammation in patient populations
